Cue Biopharma Inc.

Clinical-stage biotech engineering Immuno-STAT (Selective Targeting and Alteration of T cells) biologics that selectively modulate disease-relevant T cells without broad immune suppression. Lead pipeline shifted toward CUE-401, a bifunctional TGF-β/IL-2 fusion expanding regulatory T cells for autoimmune disease, alongside oncology programs CUE-101 (HPV+ HNSCC) and CUE-102 (WT1).